Molecular and Genetic Determinants of Glioma Cell Invasion

Molecular and Genetic Determinants of Glioma Cell Invasion

A diffusely invasive nature is a major obstacle in treating a malignant brain tumor, “diffuse glioma”, which prevents neurooncologists from surgically removing the tumor cells even in combination with chemotherapy and radiation. Recently updated classification of diffuse gliomas based on distinct ge...

Full description

Bibliographic Details
Main Authors:	Kenta Masui, Yoichiro Kato, Tatsuo Sawada, Paul S. Mischel, Noriyuki Shibata
Format:	Article
Language:	English
Published:	MDPI AG 2017-12-01
Series:	International Journal of Molecular Sciences
Subjects:	glioma cell invasion microenvironment isocitrate dehydrogenase (IDH) mammalian target of rapamycin complex 2 (mTORC2) metabolic reprogramming
Online Access:	https://www.mdpi.com/1422-0067/18/12/2609

Similar Items

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
by: Juan Huang, et al.
Published: (2019-06-01)

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery
by: Patrick J. Cimino, et al.
Published: (2017-05-01)

Promoter methylation analysis of IDH genes in human gliomas
by: Simon eFlanagan, et al.
Published: (2012-12-01)

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma
by: Choi, B.D, et al.
Published: (2022)

<i>IDH</i> Mutations in Glioma: Double-Edged Sword in Clinical Applications?
by: Alisan Kayabolen, et al.
Published: (2021-07-01)

Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas
by: XiaoYong Pan, et al.
Published: (2019-11-01)

Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma
by: Kang H, et al.
Published: (2020-10-01)

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database
by: Amrit L. Pappula, et al.
Published: (2021-08-01)

Association of <i>TP53</i> Alteration with Tissue Specificity and Patient Outcome of <i>IDH1</i>-Mutant Glioma
by: Balazs Murnyak, et al.
Published: (2021-08-01)

Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
by: Yuan Gu, et al.
Published: (2020-10-01)

Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence
by: Andreas Stadlbauer, et al.
Published: (2021-04-01)

Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring
by: Myriam M. Chaumeil, et al.
Published: (2016-01-01)

Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies
by: Tommaso Sciortino, et al.
Published: (2021-08-01)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
by: Danielle Golub, et al.
Published: (2019-05-01)

Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice
by: Claudia Bürger, et al.
Published: (2017-06-01)

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT
by: Carmen Mecca, et al.
Published: (2018-04-01)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
by: Jin Young Yang, et al.
Published: (2019-06-01)

IDH1/2 (isocitrate dehydrogenase 1/2) Mutations in Gliomas : genotype-Phenotype Correlation, Prognostic impact, and Response to Irradiation
by: Wang, Xiao Wei
Published: (2012)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
by: Mee-Sup Yoon
Published: (2017-10-01)

IDH gene mutation in glioma
by: Leping Liu, et al.
Published: (2018-01-01)

Large-Scale Drug Screening in Patient-Derived IDH<sup>mut</sup> Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents
by: Philip Dao Trong, et al.
Published: (2020-06-01)

Contemporary Mouse Models in Glioma Research
by: William H. Hicks, et al.
Published: (2021-03-01)

Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment
by: Chang-Ming Zhang, et al.
Published: (2016-01-01)

Biochemical Characterization and Genetic Modeling of Glioma-Associated Mutations in Isocitrate Dehydrogenases.
by: Lopez, Giselle Yvette
Published: (2014)

Neoplastic Cells are the Major Source of MT-MMPs in <i>IDH1</i>-Mutant Glioma, Thus Enhancing Tumor-Cell Intrinsic Brain Infiltration
by: Ina Thome, et al.
Published: (2020-08-01)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
by: Thomas Leather, et al.
Published: (2017-06-01)

Rapamycin Maintains the Chondrocytic Phenotype and Interferes with Inflammatory Cytokine Induced Processes
by: Andrea De Luna-Preitschopf, et al.
Published: (2017-07-01)

A Non-invasive Radiomic Method Using 18F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma
by: Longfei Li, et al.
Published: (2019-11-01)

A Positive Feedback Loop between Sestrin2 and mTORC2 Is Required for the Survival of Glutamine-Depleted Lung Cancer Cells
by: Jun-Kyu Byun, et al.
Published: (2017-07-01)

Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer
by: Mio Harachi, et al.
Published: (2021-04-01)

Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms
by: Jacqueline Kessler, et al.
Published: (2019-06-01)

Research progress of IDH1 and IDH2 mutations in gliomas
by: Shan-shan ZHANG, et al.
Published: (2015-11-01)

Metabolism of Amino Acids in Cancer
by: Zhen Wei, et al.
Published: (2021-01-01)

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
by: Feng-Min Liu, et al.
Published: (2021-01-01)

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
by: Si-Han Wu, et al.
Published: (2014-12-01)

Transient Inhibition of mTORC1 Signaling Ameliorates Irradiation-Induced Liver Damage
by: Wuping Yang, et al.
Published: (2019-03-01)

Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target
by: Claudia Buerger
Published: (2018-11-01)

Mitochondrial genotype alters the impact of rapamycin on the transcriptional response to nutrients in Drosophila
by: John C. Santiago, et al.
Published: (2021-03-01)

The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
by: Ghada A. Soliman
Published: (2013-06-01)

Differential Role of Rapamycin in Epidermis-Induced IL-15-IGF-1 Secretion via Activation of Akt/mTORC2
by: Yang Bai, et al.
Published: (2017-07-01)